- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- Charles River to Perform Plasmid Production for Ship of Theseus
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
- Charles River Laboratories Publishes 2023 Corporate Citizenship Report
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
- Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
- Charles River Laboratories to Present at Barclays Global Healthcare Conference
More ▼
Key statistics
On Wednesday, Charles River Laboratories International Inc (CRL:NYQ) closed at 230.09, -16.33% below its 52-week high of 275.00, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 234.40 |
---|---|
High | 234.40 |
Low | 229.85 |
Bid | 190.00 |
Offer | 259.98 |
Previous close | 230.09 |
Average volume | 448.38k |
---|---|
Shares outstanding | 51.51m |
Free float | 50.58m |
P/E (TTM) | 24.93 |
Market cap | 11.85bn USD |
EPS (TTM) | 9.23 USD |
Data delayed at least 15 minutes, as of Apr 17 2024 21:10 BST.
More ▼